Pleural Effusions

Seminars in Oncology - Volume 29, Number 1, pages 62-69 (February 2002) Paul Baas

Seminars in Oncology - Volume 29, Number 1, pages 62-69 (February 2002) Paul Baas...

Another interesting study entitled "Production of intrapleural interleukin-6 in mesothelioma and its modulation by γ-interferon treatment" by Gianpaolo Monti, Marie-Claude Jaurand, Isabelle Monnet, Pascale Chretien, Laure Saint-Etienne, Lin Zeng . Alain Portier, Philippe Devillier, Pierre Galanaud, Jean Bignon, and Dominique Emilie - Cancer Res August 15, 1994 54, 4419 Here is an excerpt: "Abstract - In vivo production of monokines was analyzed in 17 human malignant pleural mesotheliomas. High concentrations of interleukin-6 (IL-6) were detected in the pleural effusion, in contrast to the low levels of IL-1β and tumor necrosis factor α. This production originated from the malignant cells, as shown by immunochemical analysis of pleural cells and the production of IL-6 from the mesothelial cell lines. intrapleural administration of recombinant human interferon γ-six patients has led to a significant reduction in intrapleural IL-6 concentrations in all cases. This treatment was associated with in situ activation of macrophages and cytotoxic T-lymphocytes, as evidenced by increased intrapleural neopterin and soluble CD8 concentration. in vitro γ-interferon had no effect on the production of IL-6 by mesothelial cell lines, but reduced growth of 3 of 6 mesothelioma cell lines. These results suggest that systemic manifestations of malignant mesothelioma, including fever, cachexia, and thrombocytosis May apply the production of IL-6 by malignant cells, and that the local infusion of γ-interferon can reduce production by stimulating antitumoral immunity and / or directly reduces the proliferation of malignant cells. "

Another interesting study called "long-term survival in peritoneal mesothelioma and the role of radiotherapy in combined modality treatment" by Gilbert S. Lederman MD, Abram Recht Dr. Terence Herman Dr. Robert Defective Dr. Joseph Corson MD, Karen H. antman MD - Cancer Volume 59, Issue 11, 1882 to 1886 pages, 1 June 1987 Here is an excerpt:. "Summary - Ten patients with peritoneal mesothelioma were treated at the Joint Center for radiation therapy between 1968 and 1985. Six out of ten patients remained free of disease at 19 + to 78 + months after diagnosis. Six patients received sequential surgical debulking, combination chemotherapy, and whole abdominal irradiation. four patients not treated with this multimodality approach died with the disease. this approach could have an impact on the natural course of peritoneal mesothelioma, and warrants further study ."

Another interesting study entitled "Somatic genetic alterations in human malignant mesothelioma (Review)." Lee WC, Testa JR. - Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA 19111, USA Int J Oncol .. 1999th January, 14 (1) :181-8 Here's an excerpt: "Summary - review of cytogenetic and molecular genetic findings in human malignant mesotheliomas (MMS) shows a composite profile of somatic genetic changes characteristic of MMS. MultiStep implies a process of tumorigenesis of this malignancy. Specifically , the emergence of multiple, recurrent cytogenetic deletions in MMS suggests that the loss and / or inactivation of tumor suppressor genes (TSGs) are critical for the development and progression of these tumors. Karyotypic and comparative genomic hybridization analysis of MMS showed frequent deletion of specific regions within chromosome arms 1p, 3P, 6Q, 9p, 15q and 22q, and subsequent loss of heterozygosity (LOH) studies have documented high frequencies of allele loss from each of these chromosomal sites. Positional candidate gene approaches have identified TSGs within two of these regions, ie, p16 / CDKN2A at 9p21 and NF2 at 22q12, which are often changed to MMS. homozygous deletion seems to be the main mechanism affecting p16/CDKN2A, while inactivating mutations in combination with loss of alleles occur in NF2 place. high-density LOH analysis of the stress minimum region of deletion in 1P, 3P, 6Q and 15q and is expected to facilitate efforts to identify national TSGs in these places that contribute to the pathogenesis of MMS. "